Eli Lilly received approval for a plant development in Pennsylvania and paid a milestone payment to Nxera Pharma.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly received approval for a plant development in Pennsylvania and paid a milestone payment to Nxera Pharma.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pennsylvania
state of the United States of America
-
Eli Lilly and Company
American pharmaceutical company
-
Nxera Pharma
company in Tokyo, Japan
Nothing else this week.
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Soutrik Banerjee is currently employed as a consultant at Eli Lilly and Company.